These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27846946)

  • 1. Appearance of lentigines in psoriasis patients treated with apremilast.
    Sfecci A; Khemis A; Lacour JP; Montaudié H; Passeron T
    J Am Acad Dermatol; 2016 Dec; 75(6):1251-1252. PubMed ID: 27846946
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast.
    Vazquez B; Gonzalez V; Molina I; Montesinos E; Ramon MD; Monteagudo C
    Clin Exp Dermatol; 2019 Jan; 44(1):66-67. PubMed ID: 29926507
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
    Kearns DG; Uppal S; Chat VS; Wu JJ
    J Drugs Dermatol; 2021 May; 20(5):582-583. PubMed ID: 33938697
    [No Abstract]   [Full Text] [Related]  

  • 4. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast induced tinnitus: An unreported side effect.
    Sule RR; Choudhary P; Salunke TS
    Indian J Pharmacol; 2021; 53(4):328-329. PubMed ID: 34414912
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic tearing induced by apremilast.
    Norris MR; Bielory L
    Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study.
    Oak ASW; Ho-Pham H; Elewski BE
    J Am Acad Dermatol; 2020 Dec; 83(6):1830-1832. PubMed ID: 32446819
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentigines within fixed drug eruption: reply to 'Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast'.
    McCarthy S; Heffron CCBB; Murphy M
    Clin Exp Dermatol; 2019 Apr; 44(3):358-359. PubMed ID: 30575106
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.